Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• RGS10 regulates cell survival and chemoresistance in ovarian cancer.
• RGS10 transcript expression is suppressed in acquired chemoresistance.
• Epigenetic silencing via DNA hypermethylation and histone deacetylation contributes to tumor suppressor gene silencing.

Purpose of the Study:

• To investigate the molecular mechanisms of RGS10 epigenetic silencing in chemoresistant ovarian cancer cells.
• To identify key epigenetic regulators involved in RGS10 suppression.
• To evaluate the therapeutic potential of targeting these regulators.

Main Methods:

• Analysis of RGS10 promoter association with epigenetic regulators (HDAC1, DNMT1) in chemoresistant A2780-AD cells.
• Gene knockdown of HDAC1 and DNMT1.
• Pharmacological inhibition of DNMT and HDAC enzymatic activity.
• Assessment of RGS10 expression and cisplatin-mediated cell death.

Main Results:

• Aberrant association of HDAC1 and DNMT1 with RGS10 promoters was identified in chemoresistant cells.
• Knockdown of HDAC1 or DNMT1, or pharmacological inhibition, significantly increased RGS10 expression.
• RGS10 restoration enhanced cisplatin-mediated ovarian cancer cell death.
• DNMT1 knockdown reduced HDAC1 binding to the RGS10 promoter, indicating DNMT1 activity is required for HDAC1 recruitment.

Conclusions:

• HDAC1 and DNMT1 contribute to RGS10 suppression in acquired ovarian cancer chemoresistance.
• Targeting HDAC1 and DNMT1 may serve as an adjuvant therapy to overcome chemoresistance.
• Restoring RGS10 expression through epigenetic modulation offers a potential strategy against ovarian cancer.